---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001004"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:15:20.105674+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics appoints David Natan to board and audit committee

## Summary
- Board increased from 8 to 9 members; David Natan appointed as Class II director until 2026 annual meeting.
- Natan replaces Avraham Ben-Tzvi as Audit Committee member; Ben-Tzvi to become paid consultant while remaining on board.
- Natan was designated by David E. Lazar under securities purchase agreement dated December 22, 2025.
- Natan is CPA and CEO of Natan & Associates; also serves on boards of Sunshine Biopharma and FIEE.

## SEC filing metadata
- accession: 0001493152-26-001004
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/0001493152-26-001004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001004
- JSON: https://secwatch.observer/filing/0001493152-26-001004.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.